---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-020181"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T04:14:31.661547+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics receives 180-day Nasdaq extension to Sept 3, 2024 to meet $1 bid price rule

## Summary
- Nasdaq granted a 180-day extension until September 3, 2024 to regain minimum $1.00 closing bid price.
- Compliance requires $1.00 bid price for at least 10 consecutive business days; can be extended up to 20 days.
- Non-compliance was first disclosed on September 6, 2023; stock continues trading on Nasdaq under CVKD.
- Company may consider a reverse stock split if it cannot meet the price requirement by the deadline.
- If compliance not regained by Sept 3, 2024, Nasdaq will delist; company could appeal to hearings panel.

## SEC filing metadata
- accession: 0001213900-24-020181
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000121390024020181/0001213900-24-020181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000121390024020181/ea0201254-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-020181
- JSON: https://secwatch.observer/filing/0001213900-24-020181.json
- Plain text: https://secwatch.observer/filing/0001213900-24-020181.txt

## Key facts
- Listing & Compliance Notices
  Cadrenal Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: March 5, 2024, the Company received written notification from Nasdaq granting the Company's request for a 180-day extension or until September 3, 2024 to regain compliance with the Rule. Compliance is generally achieved by meeting the minimum bid price of $1.00 per share (the “Price Requirement”) for a minimum of 10 consecutive business days. However, the Staff may, in its discretion, require a Company to satisfy the applicable Price Requirement for a period in excess of 10 consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company h
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000121390024020181/0001213900-24-020181-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.